Changes of activity and isoforms of alkaline sphingomyelinase (nucleotide pyrophosphatase phosphodiesterase 7) in bile from patients undergoing endoscopic retrograde cholangiopancreatography

BMC Gastroenterology

Åke Nilsson¹  Erik Hertervig¹  Mats Hall¹  Per Bergenzaun¹  Yajun Cheng²  Ulf Hindorf¹  Rui-Dong Duan² 

[1] Department of Gastroenterology, Skåne University Hospital, S-22185 Lund, Sweden;Gastroenterology & Nutrition Laboratory, BMC, B11, Department of Clinical Sciences in Lund, University of Lund, S-22184 Lund, Sweden

关键词: Liver diseases;    Cholangiocarcinoma;    Patients;    Bile;    Alk-SMase;    NPP7;   

Others  :  1121857
DOI  :  10.1186/1471-230X-14-138

 received in 2014-02-06, accepted in 2014-07-24,  发布年份 2014

【 摘 要 】

Background

Alkaline sphingomyelinase (NPP7) is an ecto-enzyme expressed in intestinal mucosa, which hydrolyses sphingomyelin (SM) to ceramide and inactivates platelet activating factor. It is also expressed in human liver and released in the bile. The enzyme may have anti-tumour and anti-inflammatory effects in colon and its levels are decreased in patients with colon cancer and ulcerative colitis. Active NPP7 is translated from a transcript of 1.4 kb, whereas an inactive form from a 1.2 kb mRNA was found in colon and liver cancer cell lines. While the roles of NPP7 in colon cancer have been intensively studied, less is known about the function and implications of NPP7 in the bile. The present study examines the changes of NPP7 in bile of patients with various hepatobiliary diseases.

Methods

Bile samples were obtained at endoscopic retrograde cholangiopancreatography (ERCP) in 59 patients with gallstone, other benign disease, tumour, and primary sclerosing cholangitis (PSC). The NPP7 activity was determined. The appearance of the 1.4 and 1.2 kb products in the bile was examined by Western blot. The results were correlated to the diseases and also plasma bilirubin and alkaline phosphatase.

Results

NPP7 activity in the tumour group was significantly lower than in the gallstone group (p < 0.05). The activity in the tumour plus PSC group was also lower than in gallstone plus other benign disease group (p < 0.05). Within the tumour group NPP7 activity was lowest in cholangiocarcinoma patients, being only 19% of that in gallstone patients. Bilirubin correlated inversely to NPP7 and was higher in the tumour than in the gallstone group. Western blot identified both the 1.4 kb and the 1.2 kb products in most bile samples. The density ratio for the 1.4/1.2 kb products correlated to NPP7 activity significantly. Two patients (one PSC and one cholangiocarcinoma) lacking NPP7 activity had only the 1.2 kb form in bile.

Conclusion

NPP7 activity and the ratio of 1.4/1.2 kb products in bile are significantly decreased in malignancy, particularly in cholangiocarcinoma. The implications of the finding in diagnosis of cholangiocarcinoma and 1.2 kb product in hepatobiliary diseases require further investigation.

【 授权许可】

   
2014 Duan et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Duan RD, Hertervig E, Nyberg L, Hauge T, Sternby B, Lillienau J, Farooqi A, Nilsson A: Distribution of alkaline sphingomyelinase activity in human beings and animals. Tissue and species differences. Dig Dis Sci 1996, 41(9):1801-1806.
• [2]Nilsson Å: The presence of sphingomyelin- and ceramide-cleaving enzymes in the small intestinal tract. Biochim Biophys Acta 1969, 176:339-347.
• [3]Wu J, Liu F, Nilsson A, Duan RD: Pancreatic trypsin cleaves intestinal alkaline sphingomyelinase from mucosa and enhances the sphingomyelinase activity. Am J Physiol Gastrointest Liver Physiol 2004, 287(5):G967-G973.
• [4]Duan RD, Cheng Y, Tauschel HD, Nilsson A: Effects of ursodeoxycholate and other bile salts on levels of rat intestinal alkaline sphingomyelinase: a potential implication in tumorigenesis. Dig Dis Sci 1998, 43(1):26-32.
• [5]Di Marzio L, Di Leo A, Cinque B, Fanini D, Agnifili A, Berloco P, Linsalata M, Lorusso D, Barone M, De Simone C, Cifone MG: Detection of alkaline sphingomyelinase activity in human stool: proposed role as a new diagnostic and prognostic marker of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(4):856-862.
• [6]Duan RD, Bergman T, Xu N, Wu J, Cheng Y, Duan J, Nelander S, Palmberg C, Nilsson A: Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family. J Biol Chem 2003, 278(40):38528-38536.
• [7]Stefan C, Jansen S, Bollen M: NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci 2005, 30(10):542-550.
• [8]Hannun YA, Obeid LM: Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008, 9(2):139-150.
• [9]Wu J, Nilsson A, Jonsson BA, Stenstad H, Agace W, Cheng Y, Duan RD: Intestinal alkaline sphingomyelinase hydrolyses and inactivates platelet-activating factor by a phospholipase C activity. Biochem J 2006, 394(Pt 1):299-308.
• [10]Yost CC, Weyrich AS, Zimmerman GA: The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses. Biochimie 2010, 92(6):692-697.
• [11]Duan RD: Alkaline sphingomyelinase: an old enzyme with novel implications. Biochim Biophys Acta 2006, 1761(3):281-291.
• [12]Zhang Y, Cheng Y, Hansen GH, Niels-Christiansen LL, Koentgen F, Ohlsson L, Nilsson A, Duan RD: Crucial role of alkaline sphingomyelinase in sphingomyelin digestion: a study on enzyme knockout mice. J Lipid Res 2011, 52(4):771-781.
• [13]Nyberg L, Duan RD, Axelsson J, Nilsson Å: Identification of an alkaline sphingomyelinase activity in human bile. Biochim Biophys Acta 1996, 1300:42-48.
• [14]Duan RD, Nilsson Å: Purification of a newly identified alkaline sphingomyelinase in human bile and effects of bile salts and phosphatidylcholine on enzyme activity. Hepatology 1997, 26:823-830.
• [15]Cheng Y, Wu J, Hertervig E, Lindgren S, Duan D, Nilsson A, Duan RD: Identification of aberrant forms of alkaline sphingomyelinase (NPP7) associated with human liver tumorigenesis. Br J Cancer 2007, 97(10):1441-1448.
• [16]Ohlsson L, Hertervig E, Jonsson BA, Duan RD, Nyberg L, Svernlov R, Nilsson A: Sphingolipids in human ileostomy content after meals containing milk sphingomyelin. Am J Clin Nutr 2010, 91(3):672-678.
• [17]Nyberg L, Nilsson Å, Lundgren P, Duan RD: Localization and capacity of sphingomyelin digestion in the rat intestinal tract. J Nutr Biochem 1997, 8:112-118.
• [18]Nyberg L, Duan RD, Nilsson A: A mutual inhibitory effect on absorption of sphingomyelin and cholesterol. J Nutr Biochem 2000, 11(5):244-249.
• [19]Hertervig E, Nilsson A, Nyberg L, Duan RD: Alkaline sphingomyelinase activity is decreased in human colorectal carcinoma. Cancer 1997, 79(3):448-453.
• [20]Sjöqvist U, Hertervig E, Nilsson A, Duan RD, Ost A, Tribukait B, Lofberg R: Chronic colitis is associated with a reduction of mucosal alkaline sphingomyelinase activity. Inflamm Bowel Dis 2002, 8(4):258-263.
• [21]Hertervig E, Nilsson A, Bjork J, Hultkrantz R, Duan RD: Familial adenomatous polyposis is associated with a marked decrease in alkaline sphingomyelinase activity: a key factor to the unrestrained cell proliferation? Br J Cancer 1999, 81(2):232-236.
• [22]Hertervig E, Nilsson A, Cheng Y, Duan RD: Purified intestinal alkaline sphingomyelinase inhibits proliferation without inducing apoptosis in HT-29 colon carcinoma cells. J Cancer Res Clin Oncol 2003, 129:577-582.
• [23]Andersson D, Kotarsky K, Wu J, Agace W, Duan RD: Expression of alkaline sphingomyelinase in yeast cells and anti-inflammatory effects of the expressed enzyme in a rat colitis model. Dig Dis Sci 2009, 54(7):1440-1448.
• [24]Jung HY, Jun S, Lee M, Kim HC, Wang X, Ji H, McCrea PD, Park JI: PAF and EZH2 induce Wnt/beta-catenin signaling hyperactivation. Mol Cell 2013, 52(2):193-205.
• [25]Wu J, Cheng Y, Nilsson A, Duan RD: Identification of one exon deletion of intestinal alkaline sphingomyelinase in colon cancer HT-29 cells and a differentiation-related expression of the wild-type enzyme in Caco-2 cells. Carcinogenesis 2004, 25(8):1327-1333.
• [26]Nilsson A, Duan RD: Absorption and lipoprotein transport of sphingomyelin. J Lipid Res 2006, 47(1):154-171.
• [27]Svetlov SI, Howard KM, Debuysere MS, Olson MS: Secretory PAF-acetylhydrolase of the rat hepatobiliary system: characterization and partial purification. Am J Physiol 1998, 274(5 Pt 1):G891-G900.
• [28]Zhou W, Chao W, Levine BA, Olson MS: Role of platelet-activating factor in hepatic responses after bile duct ligation in rats. Am J Physiol 1992, 263(5 Pt 1):G587-G592.
• [29]Duan RD, Nilsson A: Sphingolipid hydrolyzing enzymes in the gastrointestinal tract. Methods Enzymol 2000, 311:276-286.
• [30]Duan RD, Nyberg L, Nilsson A: Alkaline sphingomyelinase activity in rat gastrointestinal tract: distribution and characteristics. Biochim Biophys Acta 1995, 1259(1):49-55.
• [31]Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD: Cholangiocarcinoma. Lancet 2005, 366(9493):1303-1314.
• [32]Reddy SB, Patel T: Current approaches to the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 2006, 8(1):30-37.
• [33]Boberg KM, Lind GE: Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol 2011, 25(6):753-764.
• [34]Kummen M, Schrumpf E, Boberg KM: Liver abnormalities in bowel diseases. Best Pract Res Clin Gastroenterol 2013, 27(4):531-542.
• [35]Modrek B, Lee C: A genomic view of alternative splicing. Nat Genet 2002, 30(1):13-19.
• [36]Venables JP: Aberrant and alternative splicing in cancer. Cancer Res 2004, 64(21):7647-7654.
• [37]Wu J, Hansen GH, Nilsson A, Duan RD: Functional studies of human intestinal alkaline sphingomyelinase by deglycosylation and mutagenesis. Biochem J 2005, 386(Pt 1):153-160.
• [38]Hakomori S: Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A 2002, 99(16):10231-10233.